This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
By This Author:
« Back
Page 1 of 593

ASCO '15: Merck, Bristol Drugs Boost Immune System to Kill Broad Swath of Cancer Types

By Adam Feuerstein

The class of cancer immunotherapy drugs which target the protein PD-1 is proving to be effective against advanced liver, head and neck, lung and colon cancers.

02:00PM 05/29/15

Puma Bio Restricting Access to Breast Cancer Event at ASCO Chicago

By Adam Feuerstein

Puma Bio, embroiled in controversy over its breast cancer drug neratinib, is turning away some people from a company event during the American Society of Clinical Oncology (ASCO) annual meeting.

10:18AM 05/28/15

Biotech Stock Mailbag: ASCO Preview, CAR-T stocks, MannKind, Hate Mail!

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

06:01AM 05/22/15

IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price

By Adam Feuerstein

IsoRay does a poor job selling radioactive 'seeds' for use in cancer radiation therapy but makes up for it by issuing a lot of promotional press releases.

11:36AM 05/21/15

Bluebird Bio First Look at Gene Therapy for Sickle Cell Disease

By Adam Feuerstein

After four and a half months of follow-up, the sickle cell patient's blood contained 24% 'marked' beta globin, a measure of normally functioning hemoglobin, Bluebird announced Thursday.

07:24AM 05/21/15

FDA Tells Sarepta Therapeutics: Come on Down With Your DMD Drug!

By Adam Feuerstein

Sarepta Therapeutics received the green light from U.S. regulators to finally file a new drug application for eteplirsen, the company's experimental therapy for Duchenne muscular dystrophy.

04:42PM 05/19/15

An Open Letter to Sell-Sider Backtracking on Kite Pharma Questions

By Adam Feuerstein

There's nothing wrong with being a biotech bull who can also raise legitimate questions and understand risks.

12:48PM 05/19/15

Bluebird Bio, Intercept Pharma Reach Accords on Pivotal Trial Designs

By Adam Feuerstein

Bluebird Bio and Intercept Pharma have reached separate agreements with regulators on the designs of key clinical trials for their respective blood disorder and fatty liver disease drugs.

11:02AM 05/19/15

Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest

By Adam Feuerstein

The speculation of another hepatitis C-related acquisition took off Monday afternoon, sparked by a rumor that Gilead executives canceled a scheduled Tuesday presentation at a health care investor conference.

06:28AM 05/19/15

Celgene's Crohn's Disease Drug Prompts Lingering Questions

By Adam Feuerstein

Mongersen is one of Celgene's most important pipeline drugs and a potential blockbuster treatment for Crohn's disease, an auto-immune disorder affecting the bowel.

11:28AM 05/18/15

« Back
Page 1 of 593

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs